Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.

• List of ContributorsPrefacePART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENTChapter 1. Drug Development in Oncology 101 by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDChapter 2. Pharmacogenomics by Molly Graveno, PharmD, BCOPChapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MDChapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MSPART 2. CLASSICAL CYTOTOXIC AGENTSChapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhDChapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MDChapter 7. Antifolate Antimetabolites by Justin Lawson, PharmD, BCOPChapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDPART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYSChapter 9. Drugs Targeting DNA Repair, Cell Cycle and Apoptosis by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhDChapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhDPART 4. ORGAN-TARGETED APPROACHESChapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhDChapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MDChapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MDChapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MDPART 5. IMMUNE-TARGETED STRATEGIESChapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MDChapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOPChapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells by Mark Yarchoan, MD and Elizabeth Jaffee, MDIndex

Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.

• List of ContributorsPrefacePART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENTChapter 1. Drug Development in Oncology 101 by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDChapter 2. Pharmacogenomics by Molly Graveno, PharmD, BCOPChapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MDChapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MSPART 2. CLASSICAL CYTOTOXIC AGENTSChapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhDChapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MDChapter 7. Antifolate Antimetabolites by Justin Lawson, PharmD, BCOPChapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDPART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYSChapter 9. Drugs Targeting DNA Repair, Cell Cycle and Apoptosis by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhDChapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhDPART 4. ORGAN-TARGETED APPROACHESChapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhDChapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MDChapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MDChapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MDPART 5. IMMUNE-TARGETED STRATEGIESChapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MDChapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOPChapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells by Mark Yarchoan, MD and Elizabeth Jaffee, MDIndex

Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.

• List of ContributorsPrefacePART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENTChapter 1. Drug Development in Oncology 101 by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDChapter 2. Pharmacogenomics by Molly Graveno, PharmD, BCOPChapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MDChapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MSPART 2. CLASSICAL CYTOTOXIC AGENTSChapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhDChapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MDChapter 7. Antifolate Antimetabolites by Justin Lawson, PharmD, BCOPChapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhDPART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYSChapter 9. Drugs Targeting DNA Repair, Cell Cycle and Apoptosis by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhDChapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhDPART 4. ORGAN-TARGETED APPROACHESChapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhDChapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MDChapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MDChapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MDPART 5. IMMUNE-TARGETED STRATEGIESChapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MDChapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOPChapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells by Mark Yarchoan, MD and Elizabeth Jaffee, MDIndex